Nutlin-3 downregulates p53 phosphorylation on serine392 and induces apoptosis in hepatocellular carcinoma cells

키워드

참고문헌 (34)

1. Jemal, A., "Global cancer statistics", CA- Cancer J. Clin, 61, pp.69~90 (2011)
2. Farazi, P. A., "Hepatocellular carcinoma pathogenesis: from genes to environment", Nat. Rev. Cancer, 6, pp.674~687 (2006)
3. Petitjean, A., "TP53 mutations in human cancers:functional selection and impact on cancer prognosis and outcomes", Oncogene, 26, pp.2157~2165 (2007)
4. Lee, S. H., "Structural Origin for the Transcriptional Activity of Human p 53", BMB Rep, 34, pp.73~79 (2001)
5. Haupt, Y., "Mdm2 promotes the rapid degradation of p53", Nature, 387, pp.296~299 (1997)
6. Li, M., "Mono-versus polyubiquitination: differential control of p53 fate by Mdm2", Science, 302, pp.1972~1975 (2003)
7. Vousden, K. H, "p53 in health and disease", Nat. Rev. Mol. Cell Bio, 8, pp.275~283 (2007)
8. Kruse, J. P., "SnapShot: p53 posttranslational modifications", Cell, 133, pp.930~ (2008)
9. Cox, M. L., "Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli", Cell. Signal, 22, pp.564~571 (2010)
10. Yap, D. B. S., "Ser392 phosphorylation regulates the oncogenic function of mutant p53", Cancer Res, 64, pp.4749~4754 (2004)
11. Sakaguchi, K., "Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53", Biochemistry, 36, pp.10117~10124 (1997)
12. Achison, M, "Hypoxia attenuates the p53 response to cellular damage", Oncogene, 22, pp.3431~3440 (2003)
13. Matsumoto, M., "Prognostic significance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma", Oncology, 67, pp.143~150 (2004)
14. Bar, J. K., "Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors", Int. J. Gynecol. Cancer, 19, pp.1322~1328 (2009)
15. Kim, Y. Y., "Modification of serine 392 is a critical event in the regulation of p53 nuclear export and stability", FEBS Lett, 572, pp.92~98 (2004)
16. Muller, P. A, "p53 mutations in cancer", Nat. Cell Biol, 15, pp.2~8 (2013)
17. Radhakrishnan, S. K, "CDK9 phosphorylates p53 on serine residues 33, 315 and 392", Cell cycle, 5, pp.519~521 (2006)
18. Cozza, G., "Kinase CK2 Inhibition: An Update", Curr. Med. Chem, 20, pp.671~693 (2013)
19. Shangary, S, "Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy", Annu. Rev. Pharmacol, 49, pp.223~241 (2009)
20. Komarov, P. G., "A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy", Science, 285, pp.1733~1737 (1999)
21. D Amaral, J., "Targeting the p53 pathway of apoptosis", Curr. Pharm. Design, 16, pp.2493~2503 (2010)
22. Ashcroft, M., "Regulation of p53 function and stability by phosphorylation", Mol. Cell. Biol, 19, pp.1751~1758 (1999)
23. Sullivan, K. D., "The p53 circuit board", BBA-Rev. Cancer, 1825, pp.229~244 (2012)
24. Vassilev, L. T., "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2", Science, 303, pp.844~848 (2004)
25. Guan, Y. -S., "p53 gene in treatment of hepatic carcinoma: status quo", World J. Gastroentero, 13, pp.985~992 (2007)
26. Hanel, W, "Links between mutant p53 and genomic instability", J. Cell. Biochem, 113, pp.433~439 (2012)
27. Gillotin, S., "Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation", Cell Cycle, 9, pp.1390~1398 (2010)
28. Furlan, A., "Abl interconnects oncogenic Met and p53 core pathways in cancer cells", Cell Death Differ, 18, pp.1608~1616 (2011)
29. Fan, G., "p53 dephosphorylation and p21Cip1", Waf1 translocation correlate with caspase-3 activation in TGF-β1-induced apoptosis of HuH-7 cells, 2004, pp.9, 211~221
30. Matsumoto, M., "Posttranslational phosphorylation of mutant p53 protein in tumor development", Med. Mol. Morphol, 39, pp.79~87 (2006)
31. Wallace, M., "Dual-site regulation of MDM2 E3-ubiquitin ligase activity", Mol. cell, 23, pp.251~263 (2006)
32. Wang, J., "MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro", J. Gastroen. Hepatol, 26, pp.371~377 (2011)
33. Yu, Y., "Ursolic acid induces human hepatoma cell line SMMC-7721 apoptosis via p53-dependent pathway", Chinese Med. J, 123, pp.1915~1923 (2010)
34. Cai, X., "Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells", Toxicol. In Vitro, 25, pp.1385~1391 (2011)

관련 논문AI추천